NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon reported after the close of the market Thursday that its second quarter revenues jumped more than 150 percent year over year as the firm trimmed its loss.

The Germantown, Md.-based firm, which went public in early August, brought in total revenues of $6.8 million for the three months ended June 30, up sharply from $2.7 million for the second quarter of 2012.

Its net loss was cut to $6.5 million, or $2.46 per share, from $16.5 million, or $3.99 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.